Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPO107 in Advanced CD20-positive Non-Hodgkin's Lymphoma
NCT04853329Phase 1Terminated
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Jan 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of JMT601 in non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Conjupro Biotherapeutics, Inc. Primary endpoint: Recommended Phase 2 Dose at 1 year. Started Dec 2021; status: terminated.
02
Drugs
JMT601
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04853329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853329.